183 related articles for article (PubMed ID: 37072753)
1. The effect of medical innovation on the cost-effectiveness of Covid 19-related policies in the United States using a SIR model.
Atherly AJ; van den Broek-Altenburg EM
BMC Health Serv Res; 2023 Apr; 23(1):372. PubMed ID: 37072753
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States.
Ohsfeldt R; Kelton K; Klein T; Belger M; Mc Collam PL; Spiro T; Burge R; Ahuja N
Clin Ther; 2021 Nov; 43(11):1877-1893.e4. PubMed ID: 34732289
[TBL] [Abstract][Full Text] [Related]
3. Cost Benefit Analysis of Limited Reopening Relative to a Herd Immunity Strategy or Shelter in Place for SARS-CoV-2 in the United States.
Schonberger RB; Listokin YJ; Ayres I; Yaesoubi R; Shelley ZR
medRxiv; 2020 Jun; ():. PubMed ID: 32607526
[TBL] [Abstract][Full Text] [Related]
4. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
Kohli M; Maschio M; Becker D; Weinstein MC
Vaccine; 2021 Feb; 39(7):1157-1164. PubMed ID: 33483216
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
6. The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States.
Kohli MA; Maschio M; Joshi K; Lee A; Fust K; Beck E; Van de Velde N; Weinstein MC
J Med Econ; 2023; 26(1):1532-1545. PubMed ID: 37961887
[TBL] [Abstract][Full Text] [Related]
7. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
8. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
[TBL] [Abstract][Full Text] [Related]
9. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
10. Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis.
Padula WV; Malaviya S; Reid NM; Cohen BG; Chingcuanco F; Ballreich J; Tierce J; Alexander GC
J Med Econ; 2021; 24(1):1060-1069. PubMed ID: 34357843
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Laparoscopic Hysterectomy With Morcellation Compared With Abdominal Hysterectomy for Presumed Myomas.
Rutstein SE; Siedhoff MT; Geller EJ; Doll KM; Wu JM; Clarke-Pearson DL; Wheeler SB
J Minim Invasive Gynecol; 2016 Feb; 23(2):223-33. PubMed ID: 26475764
[TBL] [Abstract][Full Text] [Related]
13. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study.
Kelton K; Klein T; Murphy D; Belger M; Hille E; McCollam PL; Spiro T; Burge R
Adv Ther; 2022 Jan; 39(1):562-582. PubMed ID: 34807369
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
[TBL] [Abstract][Full Text] [Related]
16. A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea.
Jo Y; Kim SB; Jung J
J Korean Med Sci; 2023 Aug; 38(32):e250. PubMed ID: 37582500
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
Annemans L; Rémy V; Oyee J; Largeron N
Pharmacoeconomics; 2009; 27(3):231-45. PubMed ID: 19354343
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: a modelling and economic analysis study.
Drakesmith M; Collins B; Jones A; Nnoaham K; Thomas DR
BMC Health Serv Res; 2022 Sep; 22(1):1190. PubMed ID: 36138455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
